title: Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
abstract: A series of 4-dimethylamino-but-2-enoic acid [4-(3,6-dioxo-cyclohexa-1,4-dienylamino)-7-ethoxy-quinazolin-6-yl]-amide derivatives were prepared. These compounds have two independent reactive centers and were designed to function as dual irreversible inhibitors of the kinase domains of both Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) where each reactive center targets a different, non-conserved, cysteine residue located in the ATP binding pocket of these enzymes. The compounds contain a 6-(4-(dimethylamino) crotonamide) Michael acceptor group that targets Cys-773 in EGFR and a 4-(amino-[1,4]benzoquinone) moiety that targets Cys-1045 in VEGFR-2. In vitro studies indicated that most of these compounds are relatively potent inhibitors of each enzyme. These inhibitors were compared with reference compounds that lack one or both of the reactive centers. The relative dependence of the IC(50) values on the concentration of ATP used in the assays suggests that these compounds appear to function as irreversible inhibitors of each kinase.
authors.affiliation: Chemical and Screening Sciences and Oncology Research, Wyeth Research, 401 N. Middletown Road, Pearl River, NY 10965, USA. wissnea@wyeth.com
authors.forename: Allan
authors.initials: A
authors.lastname: Wissner
authors.forename: Heidi L
authors.initials: HL
authors.lastname: Fraser
authors.forename: Charles L
authors.initials: CL
authors.lastname: Ingalls
authors.forename: Russell G
authors.initials: RG
authors.lastname: Dushin
authors.forename: M Brawner
authors.initials: MB
authors.lastname: Floyd
authors.forename: Kinwang
authors.initials: K
authors.lastname: Cheung
authors.forename: Thomas
authors.initials: T
authors.lastname: Nittoli
authors.forename: Malini R
authors.initials: MR
authors.lastname: Ravi
authors.forename: Xingzhi
authors.initials: X
authors.lastname: Tan
authors.forename: Frank
authors.initials: F
authors.lastname: Loganzo
mesh_terms: D000255:Adenosine Triphosphate / Q000737:chemistry / Q000378:metabolism; D001665:Binding Sites; D001681:Biological Assay; D002478:Cells, Cultured; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D020128:Inhibitory Concentration 50; D008958:Models, Molecular; D015394:Molecular Structure; D011487:Protein Conformation / Q000187:drug effects; D047428:Protein Kinase Inhibitors / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D011799:Quinazolines / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000255:Adenosine Triphosphate; D066246:ErbB Receptors; D040301:Vascular Endothelial Growth Factor Receptor-2